Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a FCF Margin % of 20.88% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chengda Pharmaceuticals Co and its competitors. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #512 out of 961 companies in the Drug Manufacturers industry, placing it in the top 53.3%.
Is Chengda Pharmaceuticals Co's FCF Margin % too high?
Chengda Pharmaceuticals Co's current FCF Margin % is 20.88%. The Drug Manufacturers industry median FCF Margin % is 2.55. Chengda Pharmaceuticals Co's value of 20.88% is 718.8% above this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #512 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #512 out of 961 companies for FCF Margin %. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median FCF Margin % is 2.55. Chengda Pharmaceuticals Co's value of 20.88% is 718.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current FCF Margin % of 20.88% is 718.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current FCF Margin % is 20.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥33.37, compared to a current price of ¥34.59 — trading 3.7% above its estimated fair value. The current FCF Margin % is 20.88% and 718.8% above the Drug Manufacturers industry median of 2.55. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current FCF Margin % is 20.88% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥34.59 is trading 3.7% above its estimated GF Value™ of ¥33.37.
GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SZSE:301201:
FCF Margin %: 20.88%
GF Value™: ¥33.37 vs. price of ¥34.59 (3.7% above fair value)
Industry Position: 718.8% above the Drug Manufacturers median (#512 of 961)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score
Get the complete analysis for SZSE:301201
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
